Exosomes Isolated From Bone Marrow Mesenchymal Stem Cells Exert a Protective Effect on Osteoarthritis via lncRNA LYRM4-AS1-GRPR-miR-6515-5p

Xiuhui Wang, Zhuokai Li, Yin Cui, Xu Cui, Cheng Chen, Zhe WangFrontiers in Cell and Developmental Biology 2021 · DOI

Abstract

Exosomes may alleviate OA inflammation by regulating the LYRM4-AS1/GRPR/miR-6515-5p signaling pathway. This study explores the molecular mechanisms through which these bone marrow mesenchymal stem cell (BMSC)-derived vesicles exert their protective effects on chondrocytes, offering a potential cell-free therapeutic strategy for osteoarthritis.

Introduction

Osteoarthritis (OA) is a degenerative joint disease affecting over 240 million people globally. Current clinical standards, such as NSAIDs and steroid injections, focus on symptom management rather than halting disease progression and often carry significant long-term side effects.

While bone marrow mesenchymal stem cell (BMSC) transplantation has shown promise in regenerating cartilage, it faces hurdles like low cell survival post-transplantation and potential immune rejection. This paper explores exosomes—tiny, membrane-bound vesicles secreted by cells—as a "cell-free" alternative. While BMSC-exosomes were known to be protective, the specific molecular "circuitry" (the competitive endogenous RNA or ceRNA network) they use to signal chondrocytes (cartilage cells) remained a mystery until now.

Methodology

Exosome Characterization

Exosomes were isolated from human BMSCs via ultracentrifugation. To validate the isolation, the researchers used Transmission Electron Microscopy (TEM) for morphology, Nanoparticle Tracking Analysis (NTA) for size (~116 nm), and Western Blotting for specific markers including CD9, CD63, and HSP70.

Characterization of human BMSCs and isolated exosomes, including morphology (A), TEM imaging (B), size distribution (C), and protein markers (D).

OA Modeling and Molecular Mapping

To mimic the osteoarthritic environment, human chondrocytes were treated with Interleukin-1β (IL-1β), a pro-inflammatory cytokine. The team sequenced RNA from both inflammatory cells and those treated with exosomes to identify differentially expressed lncRNAs (DE-lncRNAs) and miRNAs (DE-miRNAs). This transcriptomic profile identified 907 differentially expressed lncRNAs and 25 differentially expressed miRNAs between the groups.

Dual-Luciferase Reporter Assays were employed to physically prove that specific RNAs (LYRM4-AS1, miR-6515-5p, and GRPR) interact with one another. Functional assays, including CCK-8 for viability and flow cytometry for apoptosis, measured the therapeutic impact.

Key Results

The LYRM4-AS1/miR-6515-5p/GRPR Axis

The study highlights the role of lncRNA LYRM4-AS1 as a "molecular sponge." In OA, certain microRNAs (like miR-6515-5p) suppress beneficial genes. LYRM4-AS1, delivered by exosomes, binds to these microRNAs, preventing them from targeting the 3'-UTR of GRPR mRNA—a mechanism known as a competitive endogenous RNA (ceRNA) network.

Restoring the Cellular Brake System

Osteoarthritis often involves the overactivation of the PI3K/AKT signaling pathway, which promotes inflammation. The researchers found that BMSC-exosomes markedly upregulated PTEN, a protein that acts as a natural "brake" on this pathway. Treatment with 20 µg/mL of BMSC-exosomes significantly reversed the cell death and growth inhibition caused by IL-1β.

Furthermore, exosomes successfully downregulated pro-inflammatory markers MMP13, AKT1, and GRPR. When the researchers experimentally "knocked down" LYRM4-AS1, the protective effects of the exosomes were lost, proving that this specific lncRNA is essential to the therapy's success.

Discussion and Future Work

While the results are compelling, moving from lab-grown exosomes to a standardized, injectable "cell-free" drug requires significant work. The study was primarily conducted in vitro; in vivo studies using animal models are necessary to confirm if these exosomes can navigate the complex environment of a living joint.

Additionally, the sequencing data revealed hundreds of other differentially expressed RNAs, suggesting that other signaling pathways (such as the relaxin or IL-17 pathways) likely contribute to the protective effect and warrant further investigation. Clinical translation will require scaling production and ensuring long-term stability in human patients.

Summary updated

Abstract

Exosomes may alleviate OA inflammation by regulating the LYRM4-AS1/GRPR/miR-6515-5p signaling pathway.
BibTeX
@inproceedings{wang2021exosomes,
  author = {Xiuhui Wang and Zhuokai Li and Yin Cui and Xu Cui and Cheng Chen and Zhe Wang},
  title = {{Exosomes Isolated From Bone Marrow Mesenchymal Stem Cells Exert a Protective Effect on Osteoarthritis via lncRNA LYRM4-AS1-GRPR-miR-6515-5p}},
  booktitle = {Frontiers in Cell and Developmental Biology},
  year = {2021},
  doi = {10.3389/fcell.2021.644380},
}
Figure